WO2009082662A1 - Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia - Google Patents

Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia Download PDF

Info

Publication number
WO2009082662A1
WO2009082662A1 PCT/US2008/087336 US2008087336W WO2009082662A1 WO 2009082662 A1 WO2009082662 A1 WO 2009082662A1 US 2008087336 W US2008087336 W US 2008087336W WO 2009082662 A1 WO2009082662 A1 WO 2009082662A1
Authority
WO
WIPO (PCT)
Prior art keywords
combination
treatment
nilotinib
lymphocytic leukemia
chronic lymphocytic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/087336
Other languages
English (en)
French (fr)
Inventor
Raquel Silvia Aloyz
Lawrence Carl Panasci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to ES08864891.0T priority Critical patent/ES2459877T3/es
Priority to PL08864891T priority patent/PL2240172T3/pl
Priority to US12/809,805 priority patent/US20110028422A1/en
Priority to EP08864891.0A priority patent/EP2240172B1/en
Priority to JP2010539775A priority patent/JP2011507880A/ja
Publication of WO2009082662A1 publication Critical patent/WO2009082662A1/en
Anticipated expiration legal-status Critical
Priority to US14/524,493 priority patent/US20150051236A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to a combination which comprises (a) a DNA damaging agent; and (b) 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- ⁇ /-[5- ⁇ 4-methyl-1 H-imidazol-1-yl)-3- (trifluoromethyl)phenyl] benzamide ("nilotinib"); a pharmaceutical composition comprising such a combination and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment chronic lymphocytic leukemia (CLL); the use of such a combination for the preparation of a medicament for the treatment of CLL; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human.
  • CLL chronic lymphocytic leukemia
  • a DNA damaging agent is a nitrogen mustard analogue.
  • a nitrogen mustard analogue is selected from a group consisting of chlorambucil, chlornaphazine, estramustine, mechlorethamine, mechlorethamine oxide hydrochloride, navembichin, phenestrine, prednimustine, trofosfamide, uracil mustard, cyclophosphamide, uramustine, melphalan and bendamustine.
  • a DNA damaging agent is a nucleotide analogs, such as a purine analogue or a pyrimidine analogue.
  • a purine analogue is fludarabine.
  • CLL Chronic lymphocytic leukemia
  • US United States
  • CLL CLL
  • alkylating agents such as chlorambucil (CLB) or cyclophosphamide
  • purine analogs such as fludarabine.
  • CLL chlorambucil
  • CX cyclophosphamide
  • PCT/IB 03/05454 discloses that imatinib mesylate, the active ingredient of Gleevec®, sensitizes B-CLL lymphocytes to CLB. While imatinib in combination with CLB is currently in phase l-ll clinical study for the treatment of CLL, it has now surprisingly been found that nilotinib possesses a greater potency than imatinib in sensitizing CLL lymphocytes towards CLB.
  • nilotinib and imatinib inhibit in a similar fashion CLB- induced Rad51 -related DNA repair, but only nilotinib increased CLB-induced JH2AX.
  • Analysis of caspase-3 activation showed an increased of the apoptosis pathways mediated by JNK activation in cells treated with CLB in combination with nilotinib, but not imatinib.
  • c-abl inhibition by nilotinib leads to down regulation of the NFKB pathway involved in maintenance of survival B-CLL lymphocytes.
  • FIG. 1 Synergistic effect of nilotinib and imatinib in CLB cytotoxicity in lymphocytes from B- CLL patients. Evaluation of the synergistic effect of 1, 5 and 10 ⁇ M of nilotinib and imatinib in CLB cytotoxicity was assessed using MTT assay.
  • the I value l ⁇ 1 indicates that the CLB plus nilotinib or imatinib act synergistically. When I value or l>1 the drugs act antagonistically.
  • * : p ⁇ 0.001.
  • the present invention provides a combination for simultaneous, separate or sequential use which comprises (a) DNA-damaging agent and (b) 4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]-/V-[5-(4-methyl-1 H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt.
  • the present invention further provides said combination for simultaneous, separate or sequential use.
  • said DNA-damaging agent is a nitrogen mustard analogue.
  • the present invention provides a combination comprising (a) a nitrogen mustard analogue selected from a group consisting of chlorambucil, chlornaphazine, estramustine, mechlorethamine, mechlorethamine oxide hydrochloride, navembichin, phenestrine, prednimustine, trofosfamide , cyclophosphamide, uramustine, bendamustine, melphalan.and uracil mustard and (b) 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- ⁇ /-[5-(4-methyl-1 H- imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt.
  • the present invention further provides said combination for simultaneous, separate or sequential use.
  • the present invention provides a combination comprising (a) chlorambucil, (b) 4- methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- ⁇ /-[5- ⁇ 4-methyl-1H-imidazol-1-yl)-3- (trifluoromethyl)phenyl] benzamide, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt.
  • the present invention further provides said combination for simultaneous, separate or sequential use.
  • the present invention provides a combination comprising (a) cyclophosphamide, (b) 4- methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- ⁇ /-[5-(4-methyl-1 H-imidazol-1-yl)-3- (trifluoromethyi)phenyl] benzamide, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt.
  • the present invention further provides said combination for simultaneous, separate or sequential use.
  • the present invention provides a combination comprising (a) Bendamustine, (b) 4-methyl-3- [[4-(3-pyridinyl)-2-pyrimidinyl]amino]- ⁇ /-[5-(4-methyl-1 H-imidazol-1-yl)-3- (trifluoromethyl)phenyl] benzamide, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt.
  • the present invention further provides said combination for simultaneous, separate or sequential use.
  • the present invention provides a combination comprising (a) fludarabine and (b) 4-methyl-3- [[4-(3-pyridinyl)-2-pyrimidinyl]amino]- ⁇ /-[5-(4-methyl-1 H-imidazol-1-yl)-3- (trifluoromethyl)phenyl] benzamide, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt.
  • the present invention further provides said combination for simultaneous, separate or sequential use.
  • the present invention reports that a combination comprising a nitrogen mustard analogue selected from CLB, chlornaphazine, estramustine, mechlorethamine, mechlorethamine oxide hydrochloride, navembichin, phenestrine, prednimustine, trofosfamide or uracil mustard, particularly CLB and nilotinib, can produce a therapeutic effect which is greater than that obtainable by administration of a therapeutically effective amount of either a sole nitrogen mustard analogue, in particular CLB or nilotinib alone. More specifically, nilotinib sensitizes B-CLL lymphocytes to the treatment with CLB. - A -
  • the present invention pertains to a combination for simultaneous, separate or sequential use, such as a combined preparation or a pharmaceutical fixed combination, which comprises (a) a nitrogen mustard analogue and (b) nilotinib in which the active ingredients
  • (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier.
  • a combined preparation defines especially a "kit of parts" in the sense that the combination partners (a) and (b) as defined above can be dosed independently of each other or by use of different fixed combinations with distinguished amounts of the combination partners (a) and (b), i.e., simultaneously or at different time points.
  • the parts of the kit of parts can then, e.g., be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts.
  • the time intervals are chosen such that the effect on the treated disease in the combined use of the parts is larger than the effect which would be obtained by use of only any one of the combination partners (a) and (b).
  • (b) to be administered in the combined preparation can be varied, e.g. in order to cope with the needs of a patient sub-population to be treated or the needs of the single patient which different needs can be due to age, sex, body weight, etc. of the patients.
  • there is at least one beneficial effect e.g., a mutual enhancing of the effect of the combination partners (a) and (b), in particular a synergism, e.g. a more than additive effect, additional advantageous effects, less side effects, a combined therapeutic effect in a non-effective dosage of one or both of the combination partners (a) and (b), and very preferably a strong synergism of the combination partners (a) and (b).
  • treatment comprises the administration of the combination partners to a warmblooded animal in need of such treatment with the aim to cure the disease or to effect a delay of progression of a disease.
  • delay of progression means that the disease progression is at least slowed down or hampered by the treatment and that patients exhibit higher survival rates than patients not being treated or being treated with the monotherapy.
  • nitrogen mustard analogue refers to a cytotoxic chemotherapy agent which non-specificaily alkylates DNA.
  • nitrogen mustard anafogue refers to a group of compounds, including but not limited to CLB, chlornaphazine, estramustine, mechlorethamine, mechlorethamine oxide hydrochloride, navembichin, phenestrine, prednimustine, trofosfamide, uracil mustard cyclophosphamide, uramustine, bendamustine and melphalan.
  • chlorambucil-resistant chronic lymphocytic leukemia as used herein defines especially a chronic lymphocytic leukemia in which CLB is no longer efficient or shows a reduction of its therapeutic effectiveness.
  • CLB can be prepared according to the process described in US patent 3,046,301,
  • Nilotinib can be employed in the form of its mono-hydrochlohde mono-hydrate as disclosed in WO2007/015870.
  • the structure of the active agents cited may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications). The corresponding content thereof is hereby incorporated by reference. Any person skilled in the art is fully enable, based on these references, to manufacture and test the pharmaceutical indications and properties in standard test models, both in vitro and in vivo.
  • a combination as disclosed in the present invention for example a combination which comprises (a) a nitrogen mustard analogue, preferably CLB or cyclophosphamide, or alternatively (a) fludarabine and (b) nilotinib in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier, will be referred to hereinafter as a COMBINATION OF THE INVENTION.
  • the COMBINATIONS OF THE INVENTION exhibit beneficial effects in the treatment of CLL.
  • the proliferative disease to be treated with a COMBINATION OF THE INVENTION is CLL, which is resistant to CLB.
  • Suitable clinical studies are in particular randomized, double-blind, parallel studies in CLL patients with late stage disease. Such studies are, in particular, suitable to compare the effects of a mono-therapy using the active ingredients independent of each other and a therapy using a COMBINATION OF THE INVENTION, and to prove in particular the synergism of the active ingredients of the COMBINATIONS OF THE INVENTION.
  • the primary endpoints in such studies can be the performance status, Quality of Life scores or time to progression of the disease.
  • patients are, for example, receiving per treatment cycle of 2 weeks, daily at a dose ranging from 50 to 1000 mg of the nilotinib and CLB at a dose ranging from 0.2 to 1 mg/kg/day.
  • It is one objective of this invention to provide a pharmaceutical composition comprising a quantity, which is jointly therapeutically effective against CLL comprising the COMBINATION OF THE INVENTION.
  • the combination partners (a) and ⁇ b) can be administered together, one after the other or separately in one combined unit dosage form or in two separate unit dosage forms.
  • the unit dosage form may also be a fixed combination.
  • compositions according to the invention can be prepared in a manner known per se and are those suitable for enteral, such as oral or rectal, and parenteral administration to mammals (warm-blooded animals), including man, comprising at least one pharmacologically active combination partner alone or in combination with one or more pharmaceutically acceptable carries, especially suitable for enteral or parenteral application.
  • enteral such as oral or rectal
  • parenteral administration to mammals (warm-blooded animals), including man, comprising at least one pharmacologically active combination partner alone or in combination with one or more pharmaceutically acceptable carries, especially suitable for enteral or parenteral application.
  • one or more of the active ingredients are administered orally.
  • a therapeutically effective amount of each of the combination partners of the COMBINATION OF THE INVENTION may be administered simultaneously or sequentially and in any order, and the components may be administered separately or as a fixed combination.
  • a method for delaying the progression or treatment of CLL according to the present invention may comprise (i) administration of the first combination partner in free or pharmaceutically acceptable salt form and (ii) administration of the second combination partner in free or pharmaceutically acceptable salt form, simultaneously or sequentially in any order, in jointly therapeutically effective amounts, preferably in synergistically effective amounts, e.g. in daily dosages corresponding to the amounts described herein.
  • the individual combination partners of the COMBINATION OF THE INVENTION can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
  • administering also encompasses the use of a pro-drug of a combination partner that convert in vivo to the combination partner as such.
  • the instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly.
  • the effective dosage of each of the combination partners employed in the COMBINATION OF THE INVENTION may vary depending on the particular compound or pharmaceutical composition employed, the mode of administration, the stage of CLL being treated and the severity of the condition being treated.
  • the dosage regimen the COMBINATION OF THE INVENTION is selected in accordance with a variety of factors including the route of administration and the renal and hepatic function of the patient.
  • a physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the single active ingredients required to prevent, counter or arrest the progress of the condition.
  • Optimal precision in achieving concentration of the active ingredients within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the active ingredients' availability to target sites.
  • CLB can be administered at a dose range of 0.1 to 1 mg/kg/day, preferably at a dose range of 0.2 to 0.8 mg/kg/day. Most preferably, CLB is administered at a dose of 0.6 mg/kg/day.
  • nilotinib nilotinib are administered to warmblooded animals of about 70 kg bodyweight.
  • the invention relates also to a method for administering to a human subject suffering from CLL nilotinib or a pharmaceutically acceptable salt thereof.
  • the COMBINATION OF THE INVENTION can be a combined preparation or a pharmaceutical composition.
  • the present invention pertains to the use of a COMBINATION OF THE INVENTION for the treatment of CLL and for the preparation of a medicament for the treatment of CLL.
  • the present invention pertains to the use of CLB in combination with nilotinib for the preparation of a medicament for the treatment of CLL.
  • the present invention provides a commercial package comprising as active ingredients COMBINATION OF THE INVENTION, together with instructions for simultaneous, separate or sequential use thereof in the treatment of CLL.
  • Example I Nilotinib sensitizes CLL lymphocytes to CLB
  • A-1) Isolation of CLL Lymphocytes and cell culture Lymphocytes are isolated from the peripheral blood of CLL patients by sedimentation centrifugation on Ficoll Hypaque (Pharmacia, Uppsala, Sweden) as described previously (Christodoulopolis G. et a/., Cancer Research, 1999, 5:2178-84). Aliquots containing 1x10 6 cells/ml are sent for T-lymphocyte analysis. The percentage of contaminating T lymphocytes is determined using fluorescence- activated cell sorting analysis with CD3 antibody. The percentage of T-lymphocyte contamination in our population (expressed as a mean% ⁇ SE) is 6.4 ⁇ 1.8.
  • the WSU cell line is a B-lymphocytic ceil line derived from a CLL patient (Mohammad R.M., et al., Leukemia, 1996, 10:130-7).
  • lymphocytes and WSU CLL lymphocytes are seeded into 96-well plates in 200 ⁇ l suspensions containing 1,5x10 6 lymphocytes/ml and 1.25x10 5 cells/ml respectively in RPMI supplemented with 10% FBS. Only dose responses with linear plating efficiencies are analyzed.
  • the lymphocytes are then incubated at 37° C in the presence of various concentrations of nilotinib (0-100 ⁇ M) alone, CLB (0-100 ⁇ M) alone, or various concentrations of both drugs together.
  • the MTT assay is performed 72 hours after plating as described before (Christodoulopolis G et al., Cancer Research, 1998, 58: 1789-92) by addition of 20 ⁇ l of a solution of 5 mg/ml MTT (3-[4,5-dimethylthiazol-2-yl]2,5-diphenyl- tetrazolium bromide) in RPMI media to each well.
  • the LD 50 of CLB alone, nilotinib alone or CLB in the presence of nilotinib is defined as to be the drug concentration required to reduce the absorbance reading to 50% of the control value.
  • the percentage of surviving cells after treatment respect to vehicle treated cells is calculated as (OD treated celfs/OD untreated cells)x100.
  • a is the concentration of CLB required to produce 50% of control values in combination with nilotinib at concentration b
  • A is the concentration of CLB that produces an LD 50 without nilotinib
  • B is the concentration of nilotinib that produces an LD 50 in the absence of CLB.
  • Nilotinib possessed greater potency than imatinib in sensitizing CLL lymphocytes (16/19 samples) towards chlorambucil.
  • Lymphocytes were isolated from the peripheral blood using Ficoll- Hypaque (Pharmacia). The T-lymphocyte contamination in the isolated B-lymphocytes population was 2.30 ⁇ 2.07 (expressed as a mean % ⁇ S D. and determined by flow cytometry analysis).
  • the CLL lymphocytes (3x10 6 cells/ml) were plated in RPMI 1640 supplemented with 10% FBS and incubated in the presence of various concentrations (0-100 ⁇ M) of imatinib (Novartis), nilotinib ⁇ Novartis), chlorambucil alone (Sigma-Aldrich Co), or in combination as indicated. Control samples were incubated with the greatest volume of DMSO.
  • CLL patients A total of 21 CLL patients were enrolled on this study. Thirteen patients were clinically untreated (patients 1 to 13) and eight had received prior therapy with chlorambucil (treated patients 14 to 21). Their median age was 72 years (range 45 to 90 years) and their median WBC count was 83.7x10 9 cells/liter (range 32.87x10 9 to 256.27x10 9 cells/liter).
  • the MTT assay was utilized to determine the cytotoxicity of CLB alone, imatinib alone, nilotinib alone or the combination of CLB with 1 , 5 or 10 ⁇ M imatinib or nilotinib in lymphocytes from CLL patients.
  • sensitization of B-CLL lymphocytes to CLB is statistically more potent with 5 or 10 ⁇ M nilotinib than with imatinib (figure).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2008/087336 2007-12-21 2008-12-18 Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia Ceased WO2009082662A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES08864891.0T ES2459877T3 (es) 2007-12-21 2008-12-18 Combinación de nilotinib y clorambucil para el tratamiento de leucemia linfocítica crónica
PL08864891T PL2240172T3 (pl) 2007-12-21 2008-12-18 Kombinacja nilotynibu i chlorambucylu do leczenia przewlekłej białaczki limfocytowej
US12/809,805 US20110028422A1 (en) 2007-12-21 2008-12-18 Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia
EP08864891.0A EP2240172B1 (en) 2007-12-21 2008-12-18 Combination of nilotinib and chlorambucil for the treatment of chronic lymphocytic leukemia
JP2010539775A JP2011507880A (ja) 2007-12-21 2008-12-18 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤
US14/524,493 US20150051236A1 (en) 2007-12-21 2014-10-27 Combinations Useful for the Treatment of Chronic Lymphocytic Leukemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1570407P 2007-12-21 2007-12-21
US61/015,704 2014-06-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/809,805 A-371-Of-International US20110028422A1 (en) 2007-12-21 2008-12-18 Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia
US14/524,493 Continuation US20150051236A1 (en) 2007-12-21 2014-10-27 Combinations Useful for the Treatment of Chronic Lymphocytic Leukemia

Publications (1)

Publication Number Publication Date
WO2009082662A1 true WO2009082662A1 (en) 2009-07-02

Family

ID=40352369

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/087336 Ceased WO2009082662A1 (en) 2007-12-21 2008-12-18 Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia

Country Status (7)

Country Link
US (2) US20110028422A1 (cg-RX-API-DMAC7.html)
EP (1) EP2240172B1 (cg-RX-API-DMAC7.html)
JP (2) JP2011507880A (cg-RX-API-DMAC7.html)
ES (1) ES2459877T3 (cg-RX-API-DMAC7.html)
PL (1) PL2240172T3 (cg-RX-API-DMAC7.html)
PT (1) PT2240172E (cg-RX-API-DMAC7.html)
WO (1) WO2009082662A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
CA2941632C (en) * 2014-03-13 2023-10-24 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion
US9777572B2 (en) * 2014-11-17 2017-10-03 Baker Hughes Incorporated Multi-probe reservoir sampling device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil
WO2004005281A1 (en) 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases
US20060122186A1 (en) 2002-11-12 2006-06-08 Panasci Lawrence C Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
WO2007015870A2 (en) 2005-07-20 2007-02-08 Novartis Ag Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil
WO2004005281A1 (en) 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases
US20060122186A1 (en) 2002-11-12 2006-06-08 Panasci Lawrence C Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
WO2007015870A2 (en) 2005-07-20 2007-02-08 Novartis Ag Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALOYZ R ET AL: "STI571 SENSITIZED CLL LYMPHOCYTES TO CHLORAMBUCIL", 11 July 2003, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, PAGE(S) 1107, ISSN: 0197-016X, XP001179572 *
ALVARADO YESID ET AL: "Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia", 1 March 2007, EXPERT OPINION ON EMERGING DRUGS, ASHLEY PUBLICATIONS, GB, PAGE(S) 165 - 179, ISSN: 1472-8214, XP009098338 *
BAO ET AL: "Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors", 26 October 2007, LEUKEMIA RESEARCH, NEW YORK,NY, US, PAGE(S) 1511 - 1520, ISSN: 0145-2126, XP022317108 *
KALIL, N.; CHESON, B.D., THE ONCOLOGIST, vol. 4, 1999, pages 352 - 369
KANTARJIAN HAGOP ET AL: "NILOTINIB IN IMATINIB-RESISTANT CML AND PHILADELPHIA CHROMOSOME-POSITIVE", 15 June 2006, NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, PAGE(S) 2542 - 2551, ISSN: 1533-4406, XP009072571 *
PICCALUGA P P ET AL: "Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia", 15 September 2007, CANCER 20070915 US, VOL. 110, NR. 6, PAGE(S) 1178 - 1186, ISSN: 0008-543X 1097-0142, XP002516529 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer

Also Published As

Publication number Publication date
JP2011507880A (ja) 2011-03-10
ES2459877T3 (es) 2014-05-12
PT2240172E (pt) 2014-05-28
JP2014177487A (ja) 2014-09-25
US20110028422A1 (en) 2011-02-03
EP2240172A1 (en) 2010-10-20
PL2240172T3 (pl) 2014-08-29
EP2240172B1 (en) 2014-03-19
US20150051236A1 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
JP2023515817A (ja) ダブラフェニブ、erk阻害剤及びshp2阻害剤を含む三重の医薬品の組合せ
US8492383B2 (en) Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia
EP4297750A1 (en) Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
CN104023715B (zh) 激酶抑制剂的副作用降低剂
US20090298791A1 (en) Combinations comprising epothilones and antimetabolites
JP2005504111A (ja) 骨髄腫を処置するためのc−kit阻害剤の使用
US20150051236A1 (en) Combinations Useful for the Treatment of Chronic Lymphocytic Leukemia
TW201006823A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
AU2010235917A1 (en) Combination of organic compounds
IL292882A (en) Dosage of Bruton's tyrosine kinase inhibitor
EP1496908B1 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
US20110281813A1 (en) Method of treating c-kit positive relapsed acute myeloid leukemia
TWI674094B (zh) 治療或緩解慢性骨髓性白血病用之醫藥組合物
AU2007200677A1 (en) Combinations comprising epothilones and anti-metabolites

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08864891

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008864891

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010539775

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12809805

Country of ref document: US